<DOC>
	<DOCNO>NCT00782002</DOCNO>
	<brief_summary>The purpose study determine IMC-18F1 safe patient , also determine best dose IMC-18F1 give patient .</brief_summary>
	<brief_title>Safety Study IMC-18F1 , Treat Advanced Solid Tumors Subjects That Longer Respond Standard Therapy</brief_title>
	<detailed_description>The purpose study establish safety profile maximum tolerate dose ( MTD ) anti-VEGFR-1 monoclonal antibody IMC-18F1 administer weekly , every week , every three week patient advance solid tumor respond standard therapy standard therapy available .</detailed_description>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>1 . Patients histopathologicallydocumented , measurable non measurable { evaluable } , advance solid tumor refractory standard therapy standard therapy available ( see Section 10.2 , Tumor Response , definition measurable non measurable { evaluable } disease ) . 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤2 study entry . 3 . Able provide write informed consent . 4 . Age 18 year old . 5 . A life expectancy &gt; 3 month . 6 . Adequate hematologic function , define : absolute neutrophil count ≥1500/mm3 hemoglobin level ≥ 9gm/dL platelet count ≥100,000/mm3 7 . Adequate hepatic function , define : total bilirubin level ≤1.5 x ULN aspartate transaminase ( AST ) alanine transaminase ( ALT ) level ≤2.5 x ULN ≤5 x ULN know liver metastases 8 . Adequate renal function , define serum creatinine level ≤1.5 x ULN . 9 . Use effective contraception ( per institutional standard ) , procreative potential exists . 10 . Adequate recovery recent surgery , chemotherapy , radiation therapy . At least 28 day must elapse major surgery , prior chemotherapy , prior treatment investigational agent device , prior radiation therapy ( palliative radiation therapy allow ) . 11 . Accessible treatment followup . Patients enrol trial must treat participate center . 1 . Patients chemotherapy therapeutic radiotherapy within 28 day prior enter study patient ongoing side effect ≥ grade 2 due agent administer 28 day earlier . 2 . Uncontrolled intercurrent illness include , limited : ongoing active infection require parenteral antibiotic symptomatic congestive heart failure ( class III IV New York Heart Association classification heart disease ) leave ventricular ejection fraction ( LVEF ) &lt; 50 % . If baseline MUGA show &lt; 50 % ejection fraction , confirmatory ultrasound perform . If &lt; 50 % , patient exclude study unstable angina pectoris , angioplasty , stenting , myocardial infarction within 6 month uncontrolled hypertension ( systolic blood pressure &gt; 150 mm Hg , diastolic blood pressure &gt; 100 mm Hg , find two consecutive measurement separate 1week period despite adequate medical support ) clinically significant cardiac arrhythmia ( multifocal premature ventricular contraction , bigeminy , trigeminy , ventricular tachycardia symptomatic require treatment [ Common Terminology Criteria Adverse Events { CTCAE } , Version 3.0 , grade 3 ] asymptomatic sustain ventricular tachycardia ) uncontrolled diabetes psychiatric illness/social situation would compromise patient safety limit compliance study requirement 3 . Patients progressive symptomatic brain leptomeningeal metastasis . ( Patients history brain metastasis must receive definitive surgery radiotherapy , clinically stable , take steroid ; antiseizure medication allow ) . 4 . A serious nonhealing active wound , ulcer , bone fracture . 5 . Known human immunodeficiency virus positivity . 6 . A major surgical procedure , open biopsy , significant traumatic injury within 28 day prior treatment . 7 . Current recent use ( within 28 day ) thrombolytic agent . 8 . Current use fulldose warfarin ( exception lowdose warfarin maintain patency preexisting , permanent , indwell intravenous ( i.v . ) catheter ; patient receive warfarin , international normalize ratio [ INR ] &lt; 1.5 ) , heparin fractionate heparin exclude . 9 . Chronic daily treatment aspirin ( &gt; 325 mg/day ) , nonsteroidal antiinflammatory medication know inhibit platelet function ( cyclooxygenase2 [ COX2 ] inhibitor permit ) . 10 . A history clinical evidence deep venous arterial thrombosis ( include pulmonary embolism ) within 6 month prior study entry . 11 . Proteinuria ≥2+ routine urinalysis dipstick subsequent documentation 24hour urine collection &gt; 1 g protein . Patients genitourinary malignancy and/or requirement urinary catheter stent exclude 24hour urine protein ≥2 g. 12 . Pregnant ( confirm serum beta human chorionic gonadotropin [ βHCG ] ) breast feeding . 13 . Positive antiIMC18F1 antibody . 14 . Treatment monoclonal antibody within 6 week study entry . 15 . A history allergic reaction monoclonal antibody therapeutic protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>VEGF-A</keyword>
	<keyword>stromal cell</keyword>
	<keyword>endothelial cell</keyword>
	<keyword>malignant cell</keyword>
</DOC>